SCHEDULE 13G: Boao Biotech and Yulin Cao Disclose 16.6% Stake in Yubo International Biotech
Beneficial Ownership Disclosure
Boao Biotech Ltd and its sole director, Yulin Cao, have jointly disclosed a beneficial ownership of 16.6% of Yubo International Biotech Ltd's Class A Common Stock.
Summary
- Boao Biotech Ltd, a British Virgin Islands limited liability company, and Mr. Yulin Cao, a citizen of China, have jointly filed a Schedule 13G.
- The filing discloses that the Reporting Persons beneficially own an aggregate of 19,927,660 shares of Yubo International Biotech Ltd's Class A Common Stock.
- This ownership represents 16.6% of the Class A Common Stock outstanding.
- The percentage is based on 119,816,343 shares of Class A Common Stock outstanding as of May 13, 2025, as disclosed in Yubo International Biotech Ltd's Quarterly Report on Form 10-Q.
- Mr. Yulin Cao is the sole Director of Boao Biotech Ltd and is deemed to have shared voting and dispositive power over the securities held by Boao.
- The Reporting Persons have entered into a Joint Filing Agreement dated June 3, 2025, for this and future amendments.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership, and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- A significant beneficial ownership stake of 16.6% in Yubo International Biotech Ltd has been disclosed by Boao Biotech Ltd and its director, Yulin Cao, indicating a notable investment position.
Future Outlook
The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Yubo International Biotech Ltd's future performance or outlook.
Industry Context
This filing is a standard regulatory disclosure of a significant ownership stake in a biotech company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The disclosure of a significant 16.6% stake by Boao Biotech Ltd and Yulin Cao provides transparency regarding a major investor's position in the company.
Key Dates
| Date | Description |
|---|---|
| 01/25/2024 | Date of event which requires filing of this statement |
| May 13, 2025 | Date of Issuer's Quarterly Report on Form 10-Q, used for calculation of outstanding shares |
| June 3, 2025 | Date of Joint Filing Agreement and signature date for the Schedule 13G |
Keywords
Yubo International Biotech, Boao Biotech, Yulin Cao, Schedule 13G, beneficial ownership, Class A Common Stock, SEC filing, biotech investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.